Search

Your search keyword '"Fattori, Pier Paolo"' showing total 48 results
Start Over Author "Fattori, Pier Paolo"
48 results on '"Fattori, Pier Paolo"'

1. Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study

Author

Cavo, Michele, Fanin, Renato, Foa', Roberto, Rambaldi, Alessandro, Di Raimondo, Francesco, Rossi, Giuseppe, Boccadoro, Mario, Leoni, Pietro, Corradini, Paolo, Torelli, Giuseppe, Fioritoni, Giuseppe, Cortelazzo, Sergio, Lambertenghi Deliliers, Giorgio, La Nasa, Giorgio, Zaccaria, Alfonso, De Fabritiis, Paolo, Cascavilla, Nicola, Bosi, Alberto, Semenzato, Gianpietro, Gugliotta, Luigi, Gherlinzoni, Filippo, Angelucci, Emanuele, Martelli, Massimo Fabrizio, Petti, Maria Concetta, Leone, Giuseppe, Carella, Angelo Michele, Ciceri, Fabio, Santoro, Armando, Ferrara, Felicetto, Nobile, Francesco, D'Arco, Alfonso Maria, Levis, Alessandro, Guardigni, Luciano, Gallamini, Andrea, Musto, Pellegrino, Fattori, Pier Paolo, Galieni, Piero, Morandi, Sergio, Amadori, Dino, Gobbi, Marco, Rotoli, Bruno, Mirto, Salvatore, Lazzaro, Antonio, Paladini, Giorgio, Mozzana, Ruggero, Pinotti, Graziella, Rodeghiero, Francesco, Cantore, Nicola, Pavone, Vincenzo, Pogliani, Enrico Maria, Liberati, Anna Marina, Majolino, Ignazio, Amadori, Sergio, Lauria, Francesco, Aglietta, Massimo, Quarta, Giovanni, Storti, Sergio, Morabito, Fortunato, Capalbo, Silvana Franca, Gianni, Alessandro Massimo, Mettivier, Vincenzo, Rizzoli, Vittorio, Bernasconi, Carlo, Visani, Giuseppe, Pizzuti, Michele, La Verde, Giacinto, Avvisati, Giuseppe, Longinotti, Maurizio, Gallo, Eugenio, Dammacco, Franco, Russo, Domenico, Bacigalupo, Andrea, Musolino, Caterina, Tacchetti, Paola, Pantani, Lucia, Patriarca, Francesca, Petrucci, Maria Teresa, Zamagni, Elena, Dozza, Luca, Galli, Monica, Crippa, Claudia, Barbato, Simona, Tosi, Patrizia, Narni, Franco, Montefusco, Vittorio, Testoni, Nicoletta, Spadano, Antonio, Terragna, Carolina, Pescosta, Norbert, Marzocchi, Giulia, Cellini, Claudia, Ronconi, Sonia, Catalano, Lucio, De Sabbata, Giovanni, Cangialosi, Clotilde, Ciambelli, Fabrizio, and Elice, Francesca

Published
2020
Full Text
View/download PDF

2. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

Author

Trotman, Judith, Joske, David, Prince, H. Miles, Taylor, Kerry, Lewis, Ian D., Jonak, Constanze, Trautinger, Franz, Bechter, Oliver, Wolter, Pascal, Bron, Dominique, de Lima, Vladmir Claudio C., Sanches, Jose Antonio, Junior, Klasa, Richard, Bagot, Martine, Beylot-Barry, Marie, Dalle, Stephane, D'Incan, Michel, Dreno, Brigitte, Grange, Florent, Nicolay, Jan, Stadler, Rudolf, Weichenthal, Michael, Wobser, Marion, Assaf, Chalid, Loquai, Carmen, Quaglino, Pietro, Spina, Michele, Zinzani, Pier Luigi, Bosi, Alberto, Fattori, Pier Paolo, Grzanka, Aleksandra, Walewski, Jan, Lopez-Hernandez, Andres, Ortiz-Romero, Pablo L., Roca, Jose Juan Rifon, Canales, Silvana Novelli, Dummer, Reinhard, Illidge, Timothy, Johnson, Rod, Whittaker, Sean, Morris, Stephen, McKay, Pam, Scarisbrick, Julia, Duvic, Madeleine, Feldman, Tatyana, Akilov, Oleg, Geskin, Larisa, Horwitz, Steve, Kim, Youn H., Pro, Barbara, Kuzel, Timothy, Lerner, Adam, Eradat, Herbert, Sokol, Lubomir, Fisher, David C., Hughey, Sarah, Prince, H Miles, Kim, Youn H, Horwitz, Steven M, Sanches, Jose A, Ortiz-Romero, Pablo L, Akilov, Oleg E, Fisher, David, Dréno, Brigitte, Kuzel, Timothy M, Wang, Yinghui, Palanca-Wessels, Maria Corinna, Zagadailov, Erin, Trepicchio, William L, Zhang, Wenwen, Lin, Hui-Min, Liu, Yi, Huebner, Dirk, and Little, Meredith

Published
2017
Full Text
View/download PDF

3. Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial

Author

Vitolo, Umberto, Chiappella, Annalisa, Franceschetti, Silvia, Carella, Angelo Michele, Baldi, Ileana, Inghirami, Giorgio, Spina, Michele, Pavone, Vincenzo, Ladetto, Marco, Liberati, Anna Marina, Molinari, Anna Lia, Zinzani, Pierluigi, Salvi, Flavia, Fattori, Pier Paolo, Zaccaria, Alfonso, Dreyling, Martin, Botto, Barbara, Castellino, Alessia, Congiu, Angela, Gaudiano, Marcello, Zanni, Manuela, Ciccone, Giovannino, Gaidano, Gianluca, and Rossi, Giuseppe

Published
2014
Full Text
View/download PDF

5. Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study

Author

Tacchetti, Paola, primary, Pantani, Lucia, additional, Patriarca, Francesca, additional, Petrucci, Maria Teresa, additional, Zamagni, Elena, additional, Dozza, Luca, additional, Galli, Monica, additional, Di Raimondo, Francesco, additional, Crippa, Claudia, additional, Boccadoro, Mario, additional, Barbato, Simona, additional, Tosi, Patrizia, additional, Narni, Franco, additional, Montefusco, Vittorio, additional, Testoni, Nicoletta, additional, Spadano, Antonio, additional, Terragna, Carolina, additional, Pescosta, Norbert, additional, Marzocchi, Giulia, additional, Cellini, Claudia, additional, Galieni, Piero, additional, Ronconi, Sonia, additional, Gobbi, Marco, additional, Catalano, Lucio, additional, Lazzaro, Antonio, additional, De Sabbata, Giovanni, additional, Cangialosi, Clotilde, additional, Ciambelli, Fabrizio, additional, Musto, Pellegrino, additional, Elice, Francesca, additional, Cavo, Michele, additional, Fanin, Renato, additional, Foa', Roberto, additional, Rambaldi, Alessandro, additional, Rossi, Giuseppe, additional, Leoni, Pietro, additional, Corradini, Paolo, additional, Torelli, Giuseppe, additional, Fioritoni, Giuseppe, additional, Cortelazzo, Sergio, additional, Lambertenghi Deliliers, Giorgio, additional, La Nasa, Giorgio, additional, Zaccaria, Alfonso, additional, De Fabritiis, Paolo, additional, Cascavilla, Nicola, additional, Bosi, Alberto, additional, Semenzato, Gianpietro, additional, Gugliotta, Luigi, additional, Gherlinzoni, Filippo, additional, Angelucci, Emanuele, additional, Martelli, Massimo Fabrizio, additional, Petti, Maria Concetta, additional, Leone, Giuseppe, additional, Carella, Angelo Michele, additional, Ciceri, Fabio, additional, Santoro, Armando, additional, Ferrara, Felicetto, additional, Nobile, Francesco, additional, D'Arco, Alfonso Maria, additional, Levis, Alessandro, additional, Guardigni, Luciano, additional, Gallamini, Andrea, additional, Fattori, Pier Paolo, additional, Morandi, Sergio, additional, Amadori, Dino, additional, Rotoli, Bruno, additional, Mirto, Salvatore, additional, Paladini, Giorgio, additional, Mozzana, Ruggero, additional, Pinotti, Graziella, additional, Rodeghiero, Francesco, additional, Cantore, Nicola, additional, Pavone, Vincenzo, additional, Pogliani, Enrico Maria, additional, Liberati, Anna Marina, additional, Majolino, Ignazio, additional, Amadori, Sergio, additional, Lauria, Francesco, additional, Aglietta, Massimo, additional, Quarta, Giovanni, additional, Storti, Sergio, additional, Morabito, Fortunato, additional, Capalbo, Silvana Franca, additional, Gianni, Alessandro Massimo, additional, Mettivier, Vincenzo, additional, Rizzoli, Vittorio, additional, Bernasconi, Carlo, additional, Visani, Giuseppe, additional, Pizzuti, Michele, additional, La Verde, Giacinto, additional, Avvisati, Giuseppe, additional, Longinotti, Maurizio, additional, Gallo, Eugenio, additional, Dammacco, Franco, additional, Russo, Domenico, additional, Bacigalupo, Andrea, additional, and Musolino, Caterina, additional

Published
2020
Full Text
View/download PDF

9. Fludarabine Plus Mitoxantrone With and Without Rituximab Versus CHOP With and Without Rituximab As Front-Line Treatment for Patients With Follicular Lymphoma

Author

Zinzani, Pier Luigi, Pulsoni, Alessandro, Perrotti, Alessio, Soverini, Simona, Zaja, Francesco, De Renzo, Amalia, Storti, Sergio, Lauta, Vito Michele, Guardigni, Luciano, Gentilini, Patrizia, Tucci, Alessandra, Lia Molinari, Anna, Gobbi, Marco, Falini, Brunangelo, Fattori, Pier Paolo, Ciccone, Fabrizio, Alinari, Lapo, Martelli, Maurizio, Pileri, Stefano, Tura, Sante, and Baccarani, Michele

Published
2004
Full Text
View/download PDF

12. Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis

Author

Giuliani, Nicola, Colla, Simona, Lazzaretti, Mirca, Sala, Roberto, Roti, Giovanni, Mancini, Cristina, Bonomini, Sabrina, Lunghi, Paolo, Hojden, Magda, Genestreti, Giovenzio, Svaldi, Mirija, Coser, Paolo, Fattori, Pier Paolo, Sammarelli, Gabriella, Gazzola, Gian Carlo, Bataille, Regis, Almici, Camillo, Caramatti, Cecilia, Mangoni, Lina, and Rizzoli, Vittorio

Published
2003
Full Text
View/download PDF

15. Elderly Aggressive-Histology Non-Hodgkin's Lymphoma: First-Line VNCOP-B Regimen Experience on 350 Patients

Author

Zinzani, Pier Luigi, Storti, Sergio, Zaccaria, Alfonso, Moretti, Luciano, Magagnoli, Massimo, Pavone, Enzo, Gentilini, Patrizia, Guardigni, Luciano, Gobbi, Marco, Fattori, Pier Paolo, Falini, Brunangelo, Lauta, Vito Michele, Bendandi, Maurizio, Gherlinzoni, Filippo, De Renzo, Amalia, Zaja, Francesco, Mazza, Patrizio, Volpe, Ettore, Bocchia, Monica, Aitini, Enrico, Tabanelli, Maurizio, Leone, Giuseppe, and Tura, Sante

Published
1999
Full Text
View/download PDF

16. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

Author

Prince, H Miles, primary, Kim, Youn H, additional, Horwitz, Steven M, additional, Dummer, Reinhard, additional, Scarisbrick, Julia, additional, Quaglino, Pietro, additional, Zinzani, Pier Luigi, additional, Wolter, Pascal, additional, Sanches, Jose A, additional, Ortiz-Romero, Pablo L, additional, Akilov, Oleg E, additional, Geskin, Larisa, additional, Trotman, Judith, additional, Taylor, Kerry, additional, Dalle, Stephane, additional, Weichenthal, Michael, additional, Walewski, Jan, additional, Fisher, David, additional, Dréno, Brigitte, additional, Stadler, Rudolf, additional, Feldman, Tatyana, additional, Kuzel, Timothy M, additional, Wang, Yinghui, additional, Palanca-Wessels, Maria Corinna, additional, Zagadailov, Erin, additional, Trepicchio, William L, additional, Zhang, Wenwen, additional, Lin, Hui-Min, additional, Liu, Yi, additional, Huebner, Dirk, additional, Little, Meredith, additional, Whittaker, Sean, additional, Duvic, Madeleine, additional, Joske, David, additional, Prince, H. Miles, additional, Lewis, Ian D., additional, Jonak, Constanze, additional, Trautinger, Franz, additional, Bechter, Oliver, additional, Bron, Dominique, additional, de Lima, Vladmir Claudio C., additional, Sanches, Jose Antonio, additional, Klasa, Richard, additional, Bagot, Martine, additional, Beylot-Barry, Marie, additional, D'Incan, Michel, additional, Dreno, Brigitte, additional, Grange, Florent, additional, Nicolay, Jan, additional, Wobser, Marion, additional, Assaf, Chalid, additional, Loquai, Carmen, additional, Spina, Michele, additional, Bosi, Alberto, additional, Fattori, Pier Paolo, additional, Grzanka, Aleksandra, additional, Lopez-Hernandez, Andres, additional, Ortiz-Romero, Pablo L., additional, Roca, Jose Juan Rifon, additional, Canales, Silvana Novelli, additional, Illidge, Timothy, additional, Johnson, Rod, additional, Morris, Stephen, additional, McKay, Pam, additional, Akilov, Oleg, additional, Horwitz, Steve, additional, Kim, Youn H., additional, Pro, Barbara, additional, Kuzel, Timothy, additional, Lerner, Adam, additional, Eradat, Herbert, additional, Sokol, Lubomir, additional, Fisher, David C., additional, and Hughey, Sarah, additional

Published
2017
Full Text
View/download PDF

19. The efficacy of lenalidomide combination therapy in heavily pretreated non-Hodgkin lymphoma patients: an Italian observational, multicenter, retrospective study

Author

Zinzani, Pier Luigi, primary, Rigacci, Luigi, additional, Cox, Maria Cristina, additional, Devizzi, Liliana, additional, Fabbri, Alberto, additional, Zaja, Francesco, additional, Di Rocco, Alice, additional, Rossi, Giuseppe, additional, Storti, Sergio, additional, Fattori, Pier Paolo, additional, Argnani, Lisa, additional, and Vitolo, Umberto, additional

Published
2016
Full Text
View/download PDF

20. IL-17/IL-10 double-producing T cells: new link between infections, immunosuppression and acute myeloid leukemia

Author

Musuraca, Gerardo, primary, De Matteis, Serena, additional, Napolitano, Roberta, additional, Papayannidis, Cristina, additional, Guadagnuolo, Viviana, additional, Fabbri, Francesco, additional, Cangini, Delia, additional, Ceccolini, Michela, additional, Giannini, Maria Benedetta, additional, Lucchesi, Alessandro, additional, Ronconi, Sonia, additional, Mariotti, Paolo, additional, Savini, Paolo, additional, Tani, Monica, additional, Fattori, Pier Paolo, additional, Guidoboni, Massimo, additional, Martinelli, Giovanni, additional, Zoli, Wainer, additional, Amadori, Dino, additional, and Carloni, Silvia, additional

Published
2015
Full Text
View/download PDF

21. Low Toxicity Profile of the Combination of Bendamustine Plus Rituximab (BR) in Elderly FRAIL Patients with Newly Diagnosed DLBCL

Author

Spina, Michele, primary, Luminari, Stefano, additional, Salvi, Flavia, additional, Passamonti, Francesco, additional, Fabbri, Alberto, additional, Vitolo, Umberto, additional, Cabras, Maria Giuseppina, additional, Miglino, Maurizio, additional, Merli, Francesco, additional, Fattori, Pier Paolo, additional, Liberati, Anna Marina, additional, Zaccaria, Alfonso, additional, Tosi, Patrizia, additional, Ciancia, Rosanna, additional, Pesce, Emanuela Anna, additional, and Storti, Sergio, additional

Published
2014
Full Text
View/download PDF

22. The efficacy of lenalidomide combination therapy in heavily pretreated non-Hodgkin lymphoma patients: an Italian observational, multicenter, retrospective study.

Author

Zinzani, Pier Luigi, Rigacci, Luigi, Cox, Maria Cristina, Devizzi, Liliana, Fabbri, Alberto, Zaja, Francesco, Di Rocco, Alice, Rossi, Giuseppe, Storti, Sergio, Fattori, Pier Paolo, Argnani, Lisa, and Vitolo, Umberto

Subjects
LYMPHOMA treatment, ANTINEOPLASTIC agents, CANCER chemotherapy, DRUG efficacy, TREATMENT effectiveness, DRUG side effects
Abstract

The article discusses a study which examined the efficacy of lenalidomide in the treatment of patients with non-Hodgkin lymphoma (NHL). The study investigated a group of patients who received lenalidomide monotherapy and lenalidomide combination therapy. The researchers determined the patients' overall response rates (ORR), duration of response, progression-free survival (PFS), and abnormalities in laboratory data and adverse events (AEs).

Published
2017
Full Text
View/download PDF

23. Lenalidomide monotherapy in heavily pretreated patients with non-Hodgkin lymphoma: an Italian observational multicenter retrospective study in daily clinical practice

Author

Zinzani, Pier Luigi, primary, Rigacci, Luigi, additional, Cox, Maria Cristina, additional, Devizzi, Liliana, additional, Fabbri, Alberto, additional, Zaccaria, Alfonso, additional, Zaja, Francesco, additional, Di Rocco, Alice, additional, Rossi, Giuseppe, additional, Storti, Sergio, additional, Fattori, Pier Paolo, additional, Argnani, Lisa, additional, Tura, Sante, additional, and Vitolo, Umberto, additional

Published
2014
Full Text
View/download PDF

24. Patologic IL 17 Producing Helper T Cells In Acute Myeloid Leukemia Patients

Author

Musuraca, Gerardo, primary, Matteis, Serena De, additional, Napolitano, Roberta, additional, Fabbri, Francesco, additional, Cangini, Delia, additional, Ceccolini, Michela, additional, Giannini, Maria Benedetta, additional, Lucchesi, Alessandro, additional, Ronconi, Sonia, additional, Papayannidis, Cristina, additional, Guadagnuolo, Viviana, additional, Martinelli, Giovanni, additional, Savini, Paolo, additional, Tani, Monica, additional, Tosi, Patrizia, additional, Amadori, Dino, additional, Fattori, Pier Paolo, additional, Zoli, Wainer, additional, and Carloni, Silvia, additional

Published
2013
Full Text
View/download PDF

25. Final Results Of Phase II Study Of Lenalidomide Plus Rituximab-CHOP21 In Elderly Untreated Diffuse Large B-Cell Lymphoma Focusing On The Analysis Of Cell Of Origin: REAL07 Trial Of The Fondazione Italiana Linfomi

Author

Chiappella, Annalisa, primary, Franceschetti, Silvia, additional, Castellino, Alessia, additional, Carella, Angelo Michele, additional, Baldi, Ileana, additional, Zanni, Manuela, additional, Liberati, Anna Marina, additional, Spina, Michele, additional, Tucci, Alessandra, additional, Pavone, Vincenzo, additional, Molinari, Anna Lia, additional, Zinzani, Pier Luigi, additional, Salvi, Flavia, additional, Gaudiano, Marcello, additional, Fattori, Pier Paolo, additional, Zaccaria, Alfonso, additional, Botto, Barbara, additional, Congiu, Angela, additional, Ciccone, Giovannino, additional, Ladetto, Marco, additional, Dreyling, Martin, additional, Gaidano, Gianluca, additional, Inghirami, Giorgio, additional, Rossi, Giuseppe, additional, and Vitolo, Umberto, additional

Published
2013
Full Text
View/download PDF

26. Final Results Of a Phase II Study Of Lenalidomide In Combination With Rituximab For The Treatment Of Indolent Non Follicular Non Hodgkin Lymphoma

Author

Sacchi, Stefano, primary, Pozzi, Samantha, additional, Cesaretti, Marina, additional, Marcheselli, Luigi, additional, Buda, Gabriele, additional, Lazzaro, Antonio, additional, Baldini, Luca, additional, Di Raimondo, Francesco, additional, Musto, Pellegrino, additional, Zaccaria, Alfonso, additional, Specchia, Giorgina, additional, Vitolo, Umberto, additional, Magagnoli, Massimo, additional, Silvestris, Franco, additional, Fattori, Pier Paolo, additional, Tosi, Patrizia, additional, Liardo, Eliana Valentina, additional, Bari, Alessia, additional, and Carella, Angelo Michele, additional

Published
2013
Full Text
View/download PDF

27. Rituximab-CHOP21 Plus Lenalidomide (LR-CHOP21) Is Effective and Feasible in Elderly Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results of Phase II REAL07 Study of the Fondazione Italiana Linfomi (FIL)

Author

Chiappella, Annalisa, primary, Franceschetti, Silvia, additional, Castellino, Alessia, additional, Carella, Angelo Michele, additional, Baldi, Ileana, additional, Zanni, Manuela, additional, Liberati, Anna Marina, additional, Spina, Michele, additional, Bottelli, Chiara, additional, Pavone, Vincenzo, additional, Molinari, Anna Lia, additional, Zinzani, Pier Luigi, additional, Salvi, Flavia, additional, Fattori, Pier Paolo, additional, Zaccaria, Alfonso, additional, Botto, Barbara, additional, Congiu, Angela, additional, Ladetto, Marco, additional, Dreyling, Martin, additional, Gaidano, Gianluca, additional, Rossi, Giuseppe, additional, and Vitolo, Umberto, additional

Published
2012
Full Text
View/download PDF

28. Results of a Phase II Study of Lenalidomide in Combination with Rituximab for the Treatment of Indolent Non Follicular Non Hodgkin Lymphoma (NHL)

Author

Sacchi, Stefano, primary, Pozzi, Samantha, additional, Cesaretti, Marina, additional, Marcheselli, Luigi, additional, Liardo, Eliana Valentina, additional, Buda, Gabriele, additional, Lazzaro, Antonio, additional, Baldini, Luca, additional, Raimondo, Francesco Di, additional, Musto, Pellegrino, additional, Zaccaria, Alfonso, additional, Specchia, Giorgina, additional, Vitolo, Umberto, additional, Magagnoli, Massimo, additional, Silvestris, Franco, additional, Fattori, Pier Paolo, additional, Tosi, Patrizia, additional, and Carella, Angelo Michele, additional

Published
2012
Full Text
View/download PDF

29. Prolonged 18FDG-PET negative complete remission in a heavily pretreated, elderly patient with diffuse large B cell lymphoma treated with lenalidomide, low dose dexamethasone, and colony stimulating factor (Rd-G)

Author

Musuraca, Gerardo, primary, Fattori, Pier Paolo, additional, Ceccolini, Michela, additional, Cangini, Delia, additional, Giannini, Maria Benedetta, additional, Ronconi, Sonia, additional, Matteucci, Federica, additional, Asioli, Silvia, additional, and Amadori, Dino, additional

Published
2010
Full Text
View/download PDF

30. Superior Rate of Complete Response with up-Front Velcade-Thalidomide-Dexamethasone Versus Thalidomide-Dexamethasone in Newly Diagnosed Multiple Myeloma Is Not Affected by Adverse Prognostic Factors, Including High-Risk Cytogenetic Abnormalities.

Author

Cavo, Michele, primary, Testoni, Nicoletta, primary, Terragna, Carolina, primary, Marzocchi, Giulia, primary, Durante, Sandra, primary, Zambello, Renato, primary, Nozzoli, Chiara, primary, Pantani, Lucia, primary, Tacchetti, Paola, primary, Masini, Luciano, primary, Ceccolini, Michela, primary, Agostini, Paola, primary, Zamagni, Elena, primary, De Stefano, Valerio, primary, Tosi, Patrizia, primary, Derudas, Daniele, primary, Dessanti, Laura, primary, Ballanti, Stelvio, primary, Palmieri, Salvatore, primary, Nozza, Andrea, primary, Catania, Gioacchino, primary, Peccatori, Jacopo, primary, D’Arco, Alfonso, primary, Musto, Pellegrino, primary, Grasso, Mariella, primary, Pallotti, Maria Caterina, primary, Pasini, Silvana, primary, Fattori, Pier Paolo, primary, Baraldi, Anna, primary, Cangini, Delia, primary, Ballerini, Filippo, primary, Petrucci, Alessandro, primary, and Baccarani, Michele, primary

Published
2008
Full Text
View/download PDF

31. Lenalidomide monotherapy in heavily pretreated patients with non-Hodgkin lymphoma: an Italian observational multicenter retrospective study in daily clinical practice.

Author

Zinzani, Pier Luigi, Rigacci, Luigi, Cox, Maria Cristina, Devizzi, Liliana, Fabbri, Alberto, Zaccaria, Alfonso, Zaja, Francesco, Di Rocco, Alice, Rossi, Giuseppe, Storti, Sergio, Fattori, Pier Paolo, Argnani, Lisa, Tura, Sante, and Vitolo, Umberto

Subjects
DRUG efficacy, MEDICATION safety, DISEASE relapse prevention, LYMPHOMAS, OFF-label use (Drugs), PATIENTS
Abstract

Clinical trial results indicate that lenalidomide, an immunomodulatory drug, is a promising treatment in relapsed/refractory non-Hodgkin lymphoma (NHL). This retrospective multicenter study was conducted in patients with relapsed/refractory NHL treated with lenalidomide monotherapy through a Named Patient Program in Italy. Principal endpoints were overall response rate (ORR), safety and overall survival (OS). The ORR in 64 evaluable patients was 42.2% and was similar among patients receiving 10, 15 or 25 mg/day lenalidomide. Response rates in patients with mantle cell, diffuse large B-cell and follicular lymphoma were 45.5%, 42.1% and 20%, respectively. Among patients who responded to most recent prior therapy, ORR was 50.0% versus 36.8% in patients with refractory NHL. Mean duration of response in patients receiving any lenalidomide dose was 10.5 months; 1-year progression-free survival and OS were 50.3% and 82.6%, respectively. These findings suggest that lenalidomide is effective and safe for heavily pretreated patients with NHL in the clinical setting. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

32. Malignant Pericardial Mesothelioma. Report of two Cases, Review of the Literature and Differential Diagnosis

Author

Papi, Maximilian, primary, Genestreti, Giovenzio, additional, Tassinari, Davide, additional, Lorenzini, Paolo, additional, Serra, Silvia, additional, Ricci, Monica, additional, Pasquini, Enzo, additional, Nicolini, Mario, additional, Pasini, Giuseppe, additional, Tamburini, Emiliano, additional, Fattori, Pier Paolo, additional, and Ravaioli, Alberto, additional

Published
2005
Full Text
View/download PDF

33. Carboplatin and Gemcitabine in the Palliative Treatment of Stage IV Non-Small Cell Lung Cancer: Definitive Results of a Phase II Trial

Author

Tassinari, Davide, primary, Fochessati, Francesca, additional, Arcangeli, Valentina, additional, Sartori, Sergio, additional, Agostini, Vanessa, additional, Fantini, Manuela, additional, Genestreti, Giovenzio, additional, Grassia, Sergio, additional, Ioli, Giorgio, additional, Imola, Manuela, additional, Iorio, Domenico, additional, Mianulli, Anna Maria, additional, Monticelli, Giancarla, additional, Oliverio, Giovanni, additional, Panzini, Ilaria, additional, Papi, Maximilian, additional, Poggi, Barbara, additional, Polselli, Antonio, additional, Pulini, Stefano, additional, Tamburini, Emiliano, additional, Fattori, Pier Paolo, additional, and Ravaioli, Alberto, additional

Published
2004
Full Text
View/download PDF

38. Immunoglobulin VH Genes and CD38 Expression Analysis in B-Cell Chronic Lymphocytic Leukemia.

Author

Bagli, Laura, Zucchini, Alessandra, Innoceta, Anna Maria, Zaccaria, Alfonso, Cipriani, Raffaella, Fattori, Pier Paolo, and Ravaioli, Alberto

Subjects
IMMUNOGLOBULINS, GENETIC mutation, GENETICS, B cells, CHRONIC lymphocytic leukemia, DIAGNOSIS
Abstract

Examines the correlation of immunoglobulin heavy chain gene mutation analysis and CD38 expression on B cells in line with the clinical diagnosis of B-cell chronic lymphocytic leukemia (B-CLL). Disadvantages of immunoglobulin heavy chain gene mutation analysis as a diagnostic tool for B-CLL; Controversy regarding the usefulness of the CD38 expression levels as a B-CLL marker; Analysis of heavy mutation status and CD38 expression in several B-CLL patients.

Published
2006
Full Text
View/download PDF

39. Randomized Trial With or Without Granulocyte Colony-Stimulating Factor as Adjunct to Induction VNCOP-B Treatment of Elderly High-Grade Non-Hodgkin's Lymphoma

Author

Zinzani, Pier Luigi, Pavone, Enzo, Storti, Sergio, Moretti, Luciano, Fattori, Pier Paolo, Guardigni, Luciano, Falini, Brunangelo, Gobbi, Marco, Gentilini, Patrizia, Lauta, Vito Michele, Bendandi, Maurizio, Gherlinzoni, Filippo, Magagnoli, Massimo, Venturi, Stefamia, Aitini, Enrico, Tabanelli, Maurizio, Leone, Giuseppe, Liso, Vincenzo, and Tura, Sante

Abstract

Age is an important prognostic parameter, especially in patients with advanced high-grade non-Hodgkin's lymphoma (HG-NHL) who require more intensive and extensive therapy for any possible chance of cure. We investigated the potential of granulocyte colony-stimulating factor (G-CSF ) for reducing myelotoxicity, which is the most important dose-limiting factor for chemotherapy. Between March 1993 and June 1995, 158 previously untreated patients 60 years and older with HG-NHL were included in a cooperative randomized comparative trial and treated with a combination therapy including VNCOP-B (cyclophosphamide, mitoxantrone, vincristine, etoposide, bleomycin, and prednisone) with or without G-CSF. G-CSF was administered at 5 μg/kg/d throughout the treatment starting on day 3 of every week for 5 consecutive days. Of the 158 patients registered for the trial, 149 patients were evaluable: 77 received VNCOP-B plus G-CSF and 72 received VNCOP-B alone. The overall response rate was 81.5%, with complete response in 59%: 60% in the VNCOP-B plus G-CSF group, and 58% in the VNCOP-B group. At 30 months (median 24 months), 68% of all complete responders were alive without disease in the G-CSF group and 65% in the control group. Neutropenia occurred in 18 out of 77 (23%) of the G-CSF treated patients and in 40 out of 72 (55.5%) of the controls (P = .00005). Clinically relevant infections occurred in 4 out of 77 (5%) of the G-CSF group and in 15 out of 72 (21%) of the controls (P = .004). The delivered dose intensity was higher in patients receiving G-CSF (95% v 85%), but the difference was not statistically significant. Our data show that VNCOP-B is a feasible and effective regimen in elderly HG-NHL patients, and that the use of G-CSF reduces infection and neutropenia rates without producing any significant modifications to the dose intensity, CR rate, and relapse-free survival curve.

Published
1997
Full Text
View/download PDF

41. The efficacy of lenalidomide combination therapy in heavily pretreated non-Hodgkin lymphoma patients: an Italian observational, multicenter, retrospective study

Author

Alberto Fabbri, Pier Luigi Zinzani, Luigi Rigacci, Maria Cristina Cox, Pier Paolo Fattori, Lisa Argnani, Umberto Vitolo, Liliana Devizzi, Sergio Storti, Francesco Zaja, Giuseppe Rossi, Alice Di Rocco, Zinzani, Pier Luigi, Rigacci, Luigi, Cox, Maria Cristina, Devizzi, Liliana, Fabbri, Alberto, Zaja, Francesco, Di Rocco, Alice, Rossi, Giuseppe, Storti, Sergio, Fattori, Pier Paolo, Argnani, Lisa, and Vitolo, Umberto

Subjects
Adult, Male, Oncology, Cancer Research, medicine.medical_specialty, Combination therapy, Lenalidomide, Treatment, Non Hodgkin lymphoma, 03 medical and health sciences, 0302 clinical medicine, Hematology, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Aged, Retrospective Studies, Aged, 80 and over, The efficacy of lenalidomide combination therapy in heavily pretreated non-Hodgkin lymphoma patients: an Italian observational, multicenter, retrospective study, business.industry, Lymphoma, Non-Hodgkin, Remission Induction, Retrospective cohort study, Middle Aged, Survival Analysis, Thalidomide, Treatment Outcome, Italy, 030220 oncology & carcinogenesis, Hodgkin lymphoma, Female, Observational study, business, 030215 immunology, medicine.drug
Abstract

not available

Published
2016

42. Immunosuppressive Treg cells acquire the phenotype of effector-T cells in chronic lymphocytic leukemia patients

Author

Serena De Matteis, Giovanni Martinelli, Giulia Abbati, Tania Rossi, Roberta Napolitano, Gerardo Musuraca, Daniele Calistri, Chiara Molinari, Pier Paolo Fattori, Andrea Ghelli Luserna di Rorà, Massimiliano Bonafè, Alessandro Lucchesi, Martina Ghetti, Antonio Cuneo, Gian Matteo Rigolin, De Matteis, Serena, Molinari, Chiara, Abbati, Giulia, Rossi, Tania, Napolitano, Roberta, Ghetti, Martina, Di Rorà, Andrea Ghelli Luserna, Musuraca, Gerardo, Lucchesi, Alessandro, Rigolin, Gian Matteo, Cuneo, Antonio, Calistri, Daniele, Fattori, Pier Paolo, Bonafè, Massimiliano, and Martinelli, Giovanni

Subjects
Genetics and Molecular Biology (all), Male, Chronic lymphocytic leukemia, lcsh:Medicine, Adaptive Immunity, Biochemistry, Interleukin-23, T-Lymphocytes, Regulatory, 0302 clinical medicine, Candida albicans, Aged, 80 and over, medicine.diagnostic_test, Gene Expression Regulation, Leukemic, CLL, Effector-like Tregs, Plasticity, Tregs, Biochemistry, Genetics and Molecular Biology (all), General Medicine, Middle Aged, Acquired immune system, Phenotype, Treg, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Effector-like Treg, Cytokines, Female, Immunosuppressive Agents, T cell, chemical and pharmacologic phenomena, Peripheral blood mononuclear cell, General Biochemistry, Genetics and Molecular Biology, NO, Flow cytometry, 03 medical and health sciences, Interferon-gamma, Immune system, medicine, Humans, Aged, Innate immune system, business.industry, Research, Gene Expression Profiling, lcsh:R, medicine.disease, Leukemia, Lymphocytic, Chronic, B-Cell, Immunity, Innate, Lymphocyte Subsets, Immunology, business, 030215 immunology
Abstract

Background In chronic lymphocytic leukemia (CLL) disease onset and progression are influenced by the behavior of specific CD4+ T cell subsets, such as T regulatory cells (Tregs). Here, we focused on the phenotypic and functional characterization of Tregs in CLL patients to improve our understanding of the putative mechanism by which these cells combine immunosuppressive and effector-like properties. Methods Peripheral blood mononuclear cells were isolated from newly diagnosed CLL patients (n = 25) and healthy volunteers (n = 25). The phenotypic and functional characterization of Tregs and their subsets was assessed by flow cytometry. In vitro analysis of TH1, TH2, TH17 and Tregs cytokines was evaluated by IFN-γ, IL-4, IL-17A and IL-10 secretion assays. The transcriptional profiling of 84 genes panel was evaluated by RT2 Profiler PCR Array. Statistical analysis was carried out using exact non parametric Mann–Whitney U test. Results In all CLL samples, we found a significant increase in the frequency of IL-10-secreting Tregs and Tregs subsets, a significant rise of TH2 IL-4+ and TH17 IL-17A+ cells, and a higher percentage of IFN-γ/IL-10 and IL-4/IL-10 double-releasing CD4+ T cells. In addition, we also observed the up-regulation of innate immunity genes and the down-regulation of adaptive immunity ones. Conclusions Our data show that Tregs switch towards an effector-like phenotype in CLL patients. This multifaceted behavior is accompanied by an altered cytokine profiling and transcriptional program of immune genes, leading to a dysfunction in immune response in the peripheral blood environment of CLL patients. Electronic supplementary material The online version of this article (10.1186/s12967-018-1545-0) contains supplementary material, which is available to authorized users.

Published
2018

43. Atypical presentations of thrombotic thrombocytopenic purpura in middle-aged women with recurrent cerebral macrovascular thrombosis: a case report

Author

Pier Paolo Fattori, Alessandro Lucchesi, Silvia Carloni, Andrea Casadei Gardini, Sonia Ronconi, Gerardo Musuraca, Mariasanta Napolitano, Lucchesi, A., Fattori, P., Ronconi, S., Carloni, S., Casadei Gardini, A., Musuraca, G., Napolitano, M., Lucchesi, Alessandro, Fattori, Pier Paolo, Ronconi, Sonia, Carloni, Silvia, Casadei Gardini, Andrea, Musuraca, Gerardo, and Napolitano, Mariasanta

Subjects
First episode, medicine.medical_specialty, business.industry, Thrombotic thrombocytopenic purpura, Hematology, General Medicine, Gene mutation, medicine.disease, Gastroenterology, Atypical Thrombotic Thrombocytopenic purpura, ADAMTS13, Schistocyte, hemic and lymphatic diseases, Internal medicine, medicine, Factor V Leiden, Rituximab, business, Stroke, medicine.drug
Abstract

Dear Editor, In the current clinical practice, minimal criteria to define thrombotic thrombocytopenic purpura (TTP) are the presence of signs of microangiopathic haemolytic anaemia and low platelet (PLT) count [1]. TTP relapses (20–50 % of cases) are defined as the recurrence of acute TTP symptoms 30 days after the first episode, while exacerbations occur within 30 days [2]. We here report on an atypical case of acquired TTP where minimal criteria were met only after many recurrent macrovascular ischemic events. A 42-year old Caucasian woman with a history of coronary and cerebral ischemic events was admitted on June 2013, following a recurrent transient ischemic attack (TIA). She had severe anaemia and thrombocytopenia with laboratory signs of intravascular haemolysis and mild renal impairment. In her past medical history, recurrent ischemic events occurred from 2008 to 2012, without known risk factors and regardless of treatment. The patient was treated with acetyl salicylic acid (100 mg daily) after the first ischemic event (stroke, in 2008) plus anticoagulation with warfarin after the third stroke (in 2010), with a good compliance . Screening for autoimmune disease, Factor V Leiden and Factor II (G20210A) gene mutations and circulating anticoagulants were normal. Blood cell count and peripheral blood smear did not show any significant abnormalities in the past, without evidence of schistocytes; a slight decrease in PLT count (92×109/L) was observed only once (in 2012), at that time, ADAMTS13 activity (ADAMTS-13: AC) was 65 %. At the current admission, ADAMTS-13: AC was 6 %, inhibitors were at high titer (2 Bethesda Units, BU). A genetic test for Upshaw-Schulman syndrome was normal. Therapeutic plasma exchange (TPE) and prednisone (1 mg/kg body weight) treatment was started and maintained until clinical and haematological remission [3]. TPE (Gambro®, Italy) was performed daily for 3 weeks with an increase of ADAMTS13: AC to 50 %. TTP exacerbated after 10 days, it was well controlled with weekly rituximab (375 mg/m body surface), for 4 weeks. A relapse occurred after 37 days with the patient presenting seizures: ADAMTS-13: AC, which was 54 % after the last treatment, had decreased to 6 %. A second course of weekly rituximab, followed by maintenance with azathioprine (50 mg twice daily for 10 days, then 50 mg, daily) was followed by clinical and haematological remission. Rituximab was re-administered for its previous rapid efficacy and to prevent further complications [4]. The patient is alive and free from recurrences for 18 months; azathioprine maintenance is still on course. ADAMTS13: AC is monitored every 4 months, and it ranges from 45 to 51 %; inhibitors are no longer detectable. * Alessandro Lucchesi alessandro.lucchesi@irst.emr.it

Published
2015

44. Pentoxifylline-Induced Apoptosis in Chronic Lymphocytic Leukemia: New Insights into Molecular Mechanism.

Author

Napolitano R, De Matteis S, Lucchesi A, Carloni S, Cangini D, Musuraca G, Liardo EV, Norata M, and Fattori PP

Subjects
Antineoplastic Agents chemistry, Cells, Cultured, Dose-Response Relationship, Drug, Drug Screening Assays, Antitumor, Humans, Leukemia, Lymphocytic, Chronic, B-Cell pathology, Leukocytes, Mononuclear drug effects, Membrane Potential, Mitochondrial drug effects, Pentoxifylline chemistry, Structure-Activity Relationship, Antineoplastic Agents pharmacology, Apoptosis drug effects, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy, NF-kappa B antagonists & inhibitors, Pentoxifylline pharmacology, Proto-Oncogene Proteins c-bcl-2 antagonists & inhibitors
Abstract

Background: Chronic lymphocytic leukemia (CLL) is an indolent B-lineage neoplasm, characterized by clonal expansion of CD5 positive B cells with constitutive activation of survival pathways including NF-kB. Pentoxifylline, a xanthine-derivative compound indicated for the treatment of microvascular disturbancies, has been suggested to have anti-proliferative and anti-metastatic activities in various types of cancer. In the present study we extend these data showing one of the potential molecular mechanisms through which Pentoxifylline may promote apoptosis in CLL clonal lymphocytes., Methods: Peripheral blood mononuclear cells were isolated from 15 CLL patients 0 RAI stage and 15 healthy volunteers and treated for 24 and 48 hours with Pentoxifylline. Apoptosis induction was evaluated through Annexin V and TUNEL assays. Mitochondrial membrane potential depolarization analysis, active Caspase-3 assay, reactive oxygen species generation and Western Blot were assessed to further investigate the alterations induced by Pentoxifylline., Results: We observed a statistically significant occurrence of apoptosis, DNA fragmentation and active Caspase-3 in lymphocytes from CLL patients compared to healthy volunteers after 48 hours of Pentoxifylline treatment. To clarify the molecular mechanism of the drug, we also evaluated the expression levels of NF-kB/p65 and its related proteins. In treated CLL cells, NF-kB/p65 was significantly decreased in comparison to normal cells, whereas we observed a less marked reduction of Bcl-2 expression. The treatment also induced a decrease of Mcl-1 in CLL cells with a greater down-regulation of the anti-apoptotic alternatively spliced isoform., Conclusion: These findings showed that Pentoxifylline induced apoptosis in leukemic cells through a molecular mechanism that involves the NF-kB signaling., (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.)

Published
2018
Full Text
View/download PDF

45. Immunoglobulin V(H) genes and CD38 expression analysis in B-cell chronic lymphocytic leukemia.

Author

Bagli L, Zucchini A, Innoceta AM, Zaccaria A, Cipriani R, Fattori PP, and Ravaioli A

Subjects
ADP-ribosyl Cyclase 1 genetics, Biomarkers, Tumor genetics, Case-Control Studies, Drug Resistance, Neoplasm drug effects, Drug Resistance, Neoplasm genetics, Female, Humans, Immunoglobulin Variable Region genetics, Immunoglobulin gamma-Chains genetics, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy, Leukemia, Lymphocytic, Chronic, B-Cell genetics, Male, Middle Aged, Mutation, Predictive Value of Tests, Treatment Outcome, ADP-ribosyl Cyclase 1 biosynthesis, Biomarkers, Tumor biosynthesis, Gene Expression Regulation, Leukemic drug effects, Immunoglobulin Variable Region biosynthesis, Immunoglobulin gamma-Chains biosynthesis, Leukemia, Lymphocytic, Chronic, B-Cell metabolism
Published
2006
Full Text
View/download PDF

46. [Chemotherapy in extended small-cell lung cancer. Retrospective analysis of two different series of patients treated with carboplatin and etoposide or ciclophosphamide-epidoxorubicin and etoposide].

Author

Tassinari D, Genestreti G, Pasquini E, Fantini M, Poggi B, Tamburini E, Papi M, Ioli G, Oliverio G, Fochessati F, Arcangeli V, Agostini V, Mianulli AM, Imola M, Fattori PP, and Ravaioli A

Subjects
Adult, Aged, Aged, 80 and over, Carboplatin administration & dosage, Cisplatin therapeutic use, Cyclophosphamide therapeutic use, Epirubicin therapeutic use, Etoposide administration & dosage, Etoposide therapeutic use, Female, Humans, Male, Middle Aged, Retrospective Studies, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carcinoma, Small Cell drug therapy, Lung Neoplasms drug therapy
Abstract

Although cisplatin and etoposide seem to represent the treatment of choice in Small-Cell Lung Cancer, a lot of data exist in literature supporting both the use of anthracycline-containing regimens and the use of alternating regimens where platinum-containing regimens and anthracycline-containing regimens are alternatively used as first line in the same patient. In our paper we review the outcomes of two different series of patients treated with ciclophosphamide-epidoxorubicin-etoposide (CEVP16) or carboplatin-etoposide (CBE) for extended Small-Cell Lung Cancer. Sixty-three patients (53.4%) were treated with CEVP16 and 55 patients (46.6%) with CBE. Response Rate (complete plus partial responses) was greater in patients treated with CEVP16 (49.2%) when compared with the response rate in patients treated with CBE (30.9%) (p=0.04 using the Chi-Square test); no differences were observed in the median time to progression (235 vs 199 days, using the Log-Rank test). Overall survival was greater in the CEVP16 group when compared with the CBE one (281 vs 208 days and 35.6% vs 16.3% of patients alive after 2 years of follow up for CEVP16 and CBE respectively, p=0.02 using the Log-Rank test). Although our data present all the methodological limits of the "case-series", it is interesting to observe how an anthracycline-containing regimen seems to be more effective than a platinum-containing one and how it could still play a role in the treatment of extended Small-Cell Lung Cancer.

Published
2005

47. Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients.

Author

Zinzani PL, Martelli M, Bertini M, Gianni AM, Devizzi L, Federico M, Pangalis G, Michels J, Zucca E, Cantonetti M, Cortelazzo S, Wotherspoon A, Ferreri AJ, Zaja F, Lauria F, De Renzo A, Liberati MA, Falini B, Balzarotti M, Calderoni A, Zaccaria A, Gentilini P, Fattori PP, Pavone E, Angelopoulou MK, Alinari L, Brugiatelli M, Di Renzo N, Bonifazi F, Pileri SA, and Cavalli F

Subjects
Adolescent, Adult, Aged, Aged, 80 and over, Female, Humans, Lymphoma, B-Cell mortality, Lymphoma, B-Cell pathology, Lymphoma, Large B-Cell, Diffuse mortality, Lymphoma, Large B-Cell, Diffuse pathology, Lymphoma, Large B-Cell, Diffuse therapy, Male, Mediastinal Neoplasms mortality, Mediastinal Neoplasms pathology, Middle Aged, Remission Induction methods, Retrospective Studies, Sclerosis, Survival Analysis, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Lymphoma, B-Cell therapy, Mediastinal Neoplasms therapy
Abstract

Background and Objectives: This multinational retrospective study compares the outcomes of patients with primary mediastinal large B-cell lymphoma (PMLBCL) with sclerosis after first-generation (dose-intensive regimens), third-generation (alternating regimens) and high-dose chemotherapy strategies, frequently with adjuvant radiation therapy., Design and Methods: Between August 1981 and December 1999, a total of 426 previously untreated patients with confirmed diagnosis were enrolled in 20 institutions to receive combination chemotherapy with either first generation (CHOP or CHOP-like) regimens, third generation (MACOP-B, VACOP-B, ProMACE CytaBOM) regimens or high-dose chemotherapy (HDS/ABMT)., Results: With chemotherapy, complete response (CR) rates were 49% (50/105), 51% (142/277) and 53% (23/44) with first generation, third generation and high-dose chemotherapy strategies, respectively; partial response (PR) rates were 32%, 36% and 35%, respectively. All patients who achieved CR and 124/142 (84%) with PR had radiation therapy on the mediastinum. The final CR rates became 61% for CHOP/CHOP-like regimens, 79% for MACOP-B and other regimens, and 75% for HDS/ABMT. After median follow-ups from attaining CR of 48.5 months for CHOP/CHOP-like regimens, 51.7 months for MACOP-B type regimens and 32.4 months for HDS/ABMT, relapses occurred in 15/64 (23%), 27/218 (12%) and 0/33 (0%) patients, respectively. Projected 10-year progression-free survival rates were 35%, 67% and 78%, respectively (p=0.0000). Projected 10-year overall survival rates were 44%, 71% and 77%, respectively (p=0.0000), after median follow-ups from diagnosis of 52.3 months, 54.9 months and 35.8 months, respectively., Interpretation and Conclusions: In patients with PMLBCL with sclerosis, MACOP-B plus radiation therapy may be a better strategy than other treatments; these retrospective data need to be confirmed by prospective studies. The encouraging survival results after high dose chemotherapy require confirmation in selected high-risk patients.

Published
2002

48. Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous meta-analyses.

Author

Panzini I, Gianni L, Fattori PP, Tassinari D, Imola M, Fabbri P, Arcangeli V, Drudi G, Canuti D, Fochessati F, and Ravaioli A

Subjects
Chemotherapy, Adjuvant, Humans, Immunotherapy, Odds Ratio, Prognosis, Randomized Controlled Trials as Topic, Stomach Neoplasms mortality, Stomach Neoplasms surgery, Survival Rate, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Stomach Neoplasms drug therapy
Abstract

Aims and Background: Up to now adjuvant chemotherapy after curative resection for gastric cancer (GC) has been considered an experimental approach. The results of existing phase III randomized trials comparing chemotherapy with control after surgery are controversial. Three meta-analyses have been published in recent years. It is likely that each of them presents a theoretical bias, mainly as regards the inclusion criteria of the trials. In this article we re-examine this potential bias, highlighting the differences between the present and past meta-analyses on adjuvant chemotherapy for GC., Methods: Only randomized controlled clinical trials comparing systemic adjuvant chemotherapy with control after radical resection of GC were eligible. Total mortality was assessed as outcome measure of the treatment effect and a pooled odds ratio was calculated using the Peto-Mantel-Haenszel method., Results: After the selection process 17 papers (18 comparisons) proved eligible for inclusion in the meta-analysis with a total of 3118 patients, of whom 1546 randomized to the treatment arms and 1572 to the control arms; 762 and 871 deaths occurred in the treatment and control arms, respectively. Statistical analysis suggests an absence of significant heterogeneity between the trials and a significant advantage in survival for adjuvant chemotherapy (pooled odds ratio, 0.72, 95% Cl, 0.62-0.84)., Conclusions: Our meta-analysis would seem to indicate that adjuvant chemotherapy results in a significant survival advantage in patients with GC. However, this observation undoubtedly requires confirmation in large randomized controlled trials including cisplatin before adjuvant chemotherapy after curative resection for GC can be proposed for use in clinical practice.

Published
2002

Catalog

Books, media, physical & digital resources
See catalog results